Liquidia (LQDA) Cash from Investing Activities Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -38.43% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -46.70% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -103.94% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | -174.44% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 129.18% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | -1,057.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,057.52% |
| Mar 31, 2026 | -757.58% |
| Dec 31, 2025 | 15.52% |
| Sep 30, 2025 | 47.85% |
| Jun 30, 2025 | 18.06% |
| Mar 31, 2025 | 47.12% |
| Dec 31, 2024 | -2,220.39% |
| Sep 30, 2024 | 83.32% |
| Jun 30, 2024 | -430.86% |
| Mar 31, 2024 | -71.43% |
| Dec 31, 2023 | 58.04% |
| Sep 30, 2023 | -11,043.62% |
| Jun 30, 2023 | -12,050.00% |
| Dec 31, 2022 | -2,355.00% |
| Jun 30, 2022 | 94.29% |
| Dec 31, 2021 | -102.08% |
| Jun 30, 2021 | 91.43% |
| Mar 31, 2021 | 71.46% |